SONY

Product Data Sheet

Brilliant Violet 421™ anti-human CD45

Catalog # / Size: 2120160 / 100 tests
2120155 / 25 tests

Clone: HI30

Isotype: Mouse IgG1, κ

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Workshop Number: IV N816

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD45 (clone HI30) Brilliant Violet 421™ (filled histogram) or mouse IgG1, κ Brilliant Violet 421™ isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections and formalin-fixed paraffin-embedded tissue sections[9], inhibition of CD45 functions4, immunofluorescence[11], and Western blotting3.

It was found that the HI30 clone and the 2D1 clone can cross block each other's binding.

Application References:

1. Knapp W, *et al.* 1989. Leucocyte Typing IV. Oxford University Press. New York.
2. Kishihara K, *et al.* 1993. *Cell* 74:143.
3. Esser M, *et al.* 2001. *J. Virol.* 75:6173. (WB)
4. Yamada T, *et al.* 2002. *J. Biol. Chem.* 277:28830.
5. Nagano M, *et al.* 2007. *Blood* 110:151.

Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com

6. Jiang Q, *et al.* 2008. *Blood* 112:2858. PubMed
7. Morozov A, *et al.* 2010. *Clin Cancer Res.* 16:5630. PubMed
8. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
9. Friedman T, *et al.* 1999. *J. Immunol.* 162:5256. (IHC)
10. Oeztuerk-Winder F, *et al.* 2012. *EMBO J.* 31:3431. (FC) PubMed
11. Rees LE, *et al.* 2003. *Clin. Exp. Immunol.* 134:497. (IF)
12. Lee J, *et al.* 2015. *J Exp Med.* 212:385. PubMed
13. Breton G, *et al.* 2015. *J Exp Med.* 212:401. PubMed
14. Marquardt N, *et al.* 2015. *J Immunol.* 6:2467. PubMed

Description: CD45 is a 180-240 kD single chain type I membrane glycoprotein also known as leukocyte common antigen (LCA) and T200. It is a tyrosine phosphatase expressed on the plasma membrane of all hematopoietic cells, except erythrocytes and platelets. CD45 is a signaling molecule that regulates a variety of cellular processes including cell growth, differentiation, cell cycle, and oncogenic transformation. CD45 plays a critical role in T and B cell antigen receptor-mediated activation by dephosphorylating substrates including p56Lck, p59Fyn, and other Src family kinases. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to bind galectin-1 and to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4.

Antigen References:

1. Thomas M. 1989. *Annu. Rev. Immunol.* 7:339.
2. Trowbridge I, *et al.* 1994. *Annu. Rev. Immunol.*12:85.